The bottom line: a whole lot of uncertainty.
News & Analysis: Corbus Pharmaceuticals Holdings
Here's what investors need to know about this company's synthetic cannabinoid.
The clinical-stage biotech's top- and bottom-line numbers weren't the most important thing in the first quarter.
CRBP earnings call for the period ending March 31, 2019.
An analyst's favorable opinion of the biotech stock stirred up investors' excitement.
Which stock wins in a matchup between these two cannabinoid-focused biotechs?
A presentation reminded investors of the potential in the biotech's endocannabinoid candidates.
CRBP earnings call for the period ending December 31, 2018.
Investors have been ignoring this cannabis drug company's progress.
Does GW's head start in getting to market make it the better choice over Corbus?